All insights
Funding·5 min read·

Tempus AI Raises $410M in IPO, Valuation Reaches $6.1B for Precision Medicine Platform

Tempus AI successfully completes IPO raising $410M at $6.1B valuation, becoming the largest healthcare AI public offering in 2024. The precision medicine platform processes genomic and clinical data to guide cancer treatment decisions.

World Health AI Summit

<div class="space-y-8"> <div class="bg-gradient-to-br from-green-900/20 to-emerald-900/20 rounded-2xl p-8 border border-green-700/30"> <h2 class="text-2xl font-bold text-white mb-4">IPO Overview</h2> <p class="text-gray-100 text-lg leading-relaxed"> <strong class="text-white">Tempus AI</strong>, founded by Groupon co-founder Eric Lefkofsky, successfully completed its initial public offering in June 2024, raising <strong class="text-white">$410 million</strong> at a valuation of <strong class="text-white">$6.1 billion</strong>, marking the largest healthcare AI public offering this year. </p> </div> <div class="grid grid-cols-1 md:grid-cols-2 gap-6 my-10"> <div class="bg-gray-900/50 rounded-xl p-6 border border-gray-700"> <h4 class="text-sm font-semibold text-gray-400 uppercase tracking-wide mb-3">Offering Size</h4> <div class="text-3xl font-bold text-green-400 mb-1">$410M</div> <p class="text-sm text-gray-400">Largest healthcare AI IPO 2024</p> </div> <div class="bg-gray-900/50 rounded-xl p-6 border border-gray-700"> <h4 class="text-sm font-semibold text-gray-400 uppercase tracking-wide mb-3">Valuation</h4> <div class="text-3xl font-bold text-blue-400 mb-1">$6.1B</div> <p class="text-sm text-gray-400">Post-IPO market cap</p> </div> <div class="bg-gray-900/50 rounded-xl p-6 border border-gray-700"> <h4 class="text-sm font-semibold text-gray-400 uppercase tracking-wide mb-3">Patient Data</h4> <div class="text-3xl font-bold text-purple-400 mb-1">4M+</div> <p class="text-sm text-gray-400">De-identified records</p> </div> <div class="bg-gray-900/50 rounded-xl p-6 border border-gray-700"> <h4 class="text-sm font-semibold text-gray-400 uppercase tracking-wide mb-3">2023 Revenue</h4> <div class="text-3xl font-bold text-orange-400 mb-1">$532M</div> <p class="text-sm text-gray-400">33% YoY growth</p> </div> </div> <div class="my-12"> <h2 class="text-3xl font-bold text-white mb-6 pb-4 border-b border-gray-800">Platform Capabilities</h2> <div class="space-y-4"> <div class="bg-gradient-to-r from-blue-900/20 to-cyan-900/20 rounded-lg p-5 border-l-4 border-blue-500"> <h4 class="text-lg font-bold text-white mb-2">Genomic Data Library</h4> <p class="text-gray-300">37,000+ patients with sequencing data for precision oncology</p> </div> <div class="bg-gradient-to-r from-purple-900/20 to-pink-900/20 rounded-lg p-5 border-l-4 border-purple-500"> <h4 class="text-lg font-bold text-white mb-2">Treatment Recommendations</h4> <p class="text-gray-300">AI algorithms match patients to personalized cancer therapies</p> </div> <div class="bg-gradient-to-r from-green-900/20 to-emerald-900/20 rounded-lg p-5 border-l-4 border-green-500"> <h4 class="text-lg font-bold text-white mb-2">Clinical Trial Matching</h4> <p class="text-gray-300">Identifies trial opportunities based on genomic profiles</p> </div> <div class="bg-gradient-to-r from-orange-900/20 to-red-900/20 rounded-lg p-5 border-l-4 border-orange-500"> <h4 class="text-lg font-bold text-white mb-2">Hospital Network</h4> <p class="text-gray-300">1,000+ hospital partners, 100K+ genomic tests annually</p> </div> </div> </div> <div class="bg-gradient-to-br from-orange-900/30 to-red-900/30 rounded-2xl p-8 border border-orange-700/50 my-12"> <h3 class="text-2xl font-bold text-white mb-4">Market Signal</h3> <p class="text-gray-100 text-lg leading-relaxed"> This IPO demonstrates strong investor confidence in AI-powered precision medicine, validating the convergence of genomics, real-world data, and clinical AI at scale. </p> </div> <div class="border-t border-gray-800 pt-6"> <p class="text-sm text-gray-500 italic"> <strong>Source:</strong> Tempus AI SEC S-1 Filing, June 2024 </p> </div> </div>

This briefing summarises publicly available research and reporting for information only. It is not medical, investment, or legal advice. Follow the references above to the primary sources.